Biovista Inc. Named Top Innovator in Life Sciences

December 16, 2009Press Releases

CHARLOTTESVILLE, Virginia, December 16 /PRNewswire/ — Biovista Inc. today announced that it was awarded the 2009 Top Innovator Presentation Award in Healthcare, at the 2009 New England Venture Summit, held on December 8th at Dedham, MA. The award, which recognizes cutting edge private companies driving the future of innovation, was granted to Biovista who competed … Read More

TIF awards contract to Biovista for the installation of the JAnaemia patient record management system

December 1, 2009Press Releases

CHARLOTTESVILLE, Virginia and ATHENS, Greeece, December 1 /PRNewswire/ — Biovista Inc. today announced the signing of a new collaboration agreement with the Thalassaemia International Federation (TIF) for the installation and support of its JAnaemia patient record management system. JAnaemia, which has been customized, in this case for beta thalassaemia patients, will be initially installed at … Read More

Biovista announces positive efficacy results in a pre-clinical trial of BVA-201 for Multiple Sclerosis

September 9, 2009Press Releases

CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ — Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both … Read More

Biovista Inc. announces positive efficacy results in a pre-clinical trial of its BVA-601 drug for Epilepsy

June 23, 2009Press Releases

 CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ — Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant … Read More

Biovista Inc. announces positive efficacy results in a pre-clinical trial of BVA-101 for Multiple Sclerosis

April 2, 2009Press Releases

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ — Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in … Read More